Dr
Susanna
Krapp

Trainee Patent Attorney

Munich Office

Chemistry

Telephone. +49(0) 891 259 9600
Email. [email protected]

Experience

Susanna studied Molecular Science at the Friedrich-Alexander University in Erlangen. Molecular sciences is a cross-disciplinary field that studies molecular materials, structures and systems. Molecular sciences serve as a basis for scientific areas such as medicine, pharmacology, chemistry, bio-molecular engineering, molecular biology and physics. Masters in Molecular Sciences also involve aspects of scientific innovation and discovery, biochemistry and chemical engineering.

Further to her studies of Molecular Science, Susanna did doctoral studies in the field of Molecular Life Science. She investigated the interaction of plant viruses with different biochemical systems of plants, which are manipulated by the plant viruses to suppress the plant immune system. In connection with this research, Susanna spent some time abroad at the Greehey Distinguished Chair in Targeted Molecular Therapeutics at the UT Health San Antonio, Texas, USA and at the Shanghai Center for Plant Stress Biology in Shanghai, China.

After focussing on Molecular Life Science in her dissertation, she has gone back to her roots in HGF's chemistry group in Munich.

Herein, she is working in the field of material science, inorganic chemistry and metallurgy.

After her trainee patent attorney program her individual cross-disciplinary knowledge in science will make her an especially qualified patent attorney.

Specialisms

Industries

Services

Qualifications

Trainee


BSC

Molecular Science

MSC

Molecular Science

PHD

Molecular Biology

Related News

Artificial intelligence inventions in healthcare – can you patent them in Europe?

Artificial Intelligence (AI) has moved from the realm of science fiction firmly into the mainstream of technological innovation. Trained AI models in some cases are able to perform data analysis …

Read article

Patenting digital mental health

Mental health and behavioural disorders have a profound impact on wellbeing worldwide, with an estimated 13% of the global population suffering from a mental health or substance use disorder [1]. …

Read article

Patenting antibodies in the US and Europe

Is the USPTO now stricter than the EPO on antibody claims? A consideration of recent developments from both sides of the pond. Patent protection for monoclonal antibodies, bispecific antibodies and …

Read article

Patentability of Simulations in Europe

Simulations offer a powerful tool in modern-day engineering. Subjecting designs to initial testing in a simulated environment will, for many designs, reduce costs owing to reduced needs to produce and …

Read article

Blockbuster blood thinning patent revoked

Summary Mr Justice Meade has revoked Bristol Myers Squibb’s (BMS) European patent No. EP1427415 (EP’415) and corresponding supplementary protection certificate (SPC) that relate to the compound Apixaban (ELIQUIS) for lack …

Read article
Event - 10th May 2022

The HGF IP in Healthcare Conference 2022

After a challenging couple of years, we are delighted to invite you to join us for HGF’s eighth annual IP in Healthcare Conference. We will review the latest intellectual property …

Event details
Event - 10th May 2022

HGF UPC events in Germany and Austria 2022

HGF is holding a webinar and an in-person event covering the UPC in Germany and Austria this Spring. The provisional phase of the Unified Patent Court (UPC) is now underway …

Event details
Event - 23rd March 2022

HGF webinar: Getting your first filing right

HGF hosted a webinar on Wednesday 23rd March on Getting your first filing right. One of the most often asked questions of patent attorneys is: “when should we file?” Both …

Event details

Let's talk

If you would like to discuss how HGF could help you, contact one of our IP specialists.